Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Clomiphene and anti‐oestrogens for ovulation induction in PCOS

This is not the most recent version

Information

DOI:
https://doi.org/10.1002/14651858.CD002249.pub4Copy DOI
Database:
  1. Cochrane Database of Systematic Reviews
Version published:
  1. 07 October 2009see what's new
Type:
  1. Intervention
Stage:
  1. Review
Cochrane Editorial Group:
  1. Cochrane Gynaecology and Fertility Group

Copyright:
  1. Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Article metrics

Altmetric:

Cited by:

Cited 0 times via Crossref Cited-by Linking

Collapse

Authors

  • Julie Brown

    Correspondence to: Obstetrics and Gynaecology, University of Auckland, Auckland, New Zealand

    [email protected]

  • Cindy Farquhar

    Obstetrics and Gynaecology, University of Auckland, Auckland, New Zealand

  • James Beck

    University of Newcastle, Jesmond, UK

  • Clare Boothroyd

    Reproductive, Endocrinology, Gynaecology and Infertility, Greenslopes Specialist Centre, Greenslopes, Australia

  • Edward Hughes

    Department of Obstetrics and Gynaecology, McMaster University, Hamilton, Canada

Contributions of authors

Julie Brown: wrote the updated version of this review including identification of new trials, data extraction and analysis.

Cindy Farquhar: initiated and conceptualised the protocol, commented on drafts of the original and updated review and assisted in the identification of new trials and data extraction for the review update.

Clare Boothroyd: wrote the initial version of the protocol and commented on drafts of the review.

James Beck: updated the protocol and performed the primary literature search, initial assessment of trials and quality analysis, data collection, analysis and wrote the initial draft of the review.

Michelle Proctor: checked the literature search, reviewed quality analysis and data collection, checked and revised the initial draft of the review.

Edward Hughes: provided clinical input for the review and commented on drafts of the review.

Sources of support

Internal sources

  • University of Newcastle Upon Tyne, School of Medicine, Newcastle Upon Tyne, UK.

  • University of Auckland, School of Medicine, Auckland, New Zealand.

External sources

  • No sources of support supplied

Declarations of interest

None known

Acknowledgements

This review includes work from a previous review on clomiphene for ovulation induction by E Hughes, J Collins and P Vandekerckhove (Hughes 1996).

The authors wish to thank Sue Hall and Jane Marjoribanks for their help and support. Thanks also to Ruth Buist for helping with the searches, Richmal Oates‐Whitehead and Anne Lethaby for translating and Neil Johnson and Ian Beck for their clinical input.

Version history

Published

Title

Stage

Authors

Version

2016 Dec 15

Clomiphene and other antioestrogens for ovulation induction in polycystic ovarian syndrome

Review

Julie Brown, Cindy Farquhar

https://doi.org/10.1002/14651858.CD002249.pub5

2009 Oct 07

Clomiphene and anti‐oestrogens for ovulation induction in PCOS

Review

Julie Brown, Cindy Farquhar, James Beck, Clare Boothroyd, Edward Hughes

https://doi.org/10.1002/14651858.CD002249.pub4

2009 Jul 08

Oral anti‐oestrogens and medical adjuncts for subfertility associated with anovulation

Review

Julie Brown , Cindy Farquhar, James Beck, Clare Boothroyd, Michelle Proctor, Edward Hughes

https://doi.org/10.1002/14651858.CD002249.pub3

2004 Jul 19

Oral anti‐oestrogens and medical adjuncts for subfertility associated with polycystic ovary syndrome

Protocol

James I Beck, Clare Boothroyd, Cindy M Farquhar

https://doi.org/10.1002/14651858.CD002249.pub2

2000 Jul 24

Oral agents for ovulation induction in subfertility associated with PCOS

Protocol

C Boothroyd, C Farquhar

https://doi.org/10.1002/14651858.CD002249

Differences between protocol and review

The inclusion criteria of this review were widened from that of the original protocol (participants with anovulation attributed to PCOS) to include all WHO group 2 causes of anovulation but excluding hyperprolactinaemia. Trials that were non‐specific but appeared to describe PCOS‐like anovulation (for example participants with progestin‐induced withdrawal bleeding) were included. Due to the age of many of the trials, particularly for clomiphene versus placebo, the most likely cause of anovulation was not described fully. In particular, the currently utilised diagnostic criteria for PCOS were not able to be met. These trials would have been excluded under the criteria of the protocol. It was felt that their results were valid and important and so the background and inclusion criteria sections were widened.

Aromatase inhibitor comparisons have been removed from this review as they will addressed within a separate protocol El Daly 2006.

Title changed from 'Oral anti‐oestrogens and medical adjuncts for subfertility associated with anovulation' to 'Clomiphene and anti‐oestrogens for ovulation induction in PCOS.

PICOs

Population
Intervention
Comparison
Outcome

The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.

See more on using PICO in the Cochrane Handbook.